Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johan Vekemans

Showing results (91-100 of 115) with videos related to

Pageof 12
Sort By:
Plos One|December 3, 2010
Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian ChildrenJohn Lusingu, Ally Olotu, Amanda Leach, et al.
Frontiers in Immunology|August 2, 2021
Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human TrialHans de Graaf, Ruth O Payne, Iona Taylor, et al.
Human Vaccines & Immunotherapeutics|March 21, 2024
Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adultsPrasad S Kulkarni, Chandrasekaran Padmapriyadarsini, Johan Vekemans, et al.
Plos One|May 11, 2011
T cell responses to the RTS,S/AS01(E) and RTS,S/AS02(D) malaria candidate vaccines administered according to different schedules to Ghanaian childrenDaniel Ansong, Kwaku P Asante, Johan Vekemans, et al.
Plos One|July 7, 2015
Ad35.CS.01-RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve AdultsChristian F Ockenhouse, Jason Regules, Donna Tosh, et al.
Plos One|October 7, 2009
Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian childrenSeth Owusu-Agyei, Daniel Ansong, Kwaku Asante, et al.
The Lancet. Infectious Diseases|June 20, 2018
The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidatesNatalie I Mazur, Deborah Higgins, Marta C Nunes, et al.
The Journal of Infectious Diseases|June 17, 2016
Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAPTommy Rampling, Katie J Ewer, Georgina Bowyer, et al.
NPJ Vaccines|October 17, 2018
Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAPTommy Rampling, Katie J Ewer, Georgina Bowyer, et al.
The New England Journal of Medicine|November 5, 2025
Safety and Immunogenicity of an rVSV Lassa Fever Vaccine CandidateElissa Malkin, Marija Zaric, Mark Kieh, et al.
Pageof 12

Showing results (91-100 of 115) with videos related to

Sort By:
Pageof 12
Plos One|December 3, 2010
Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian ChildrenJohn Lusingu, Ally Olotu, Amanda Leach, et al.
Frontiers in Immunology|August 2, 2021
Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human TrialHans de Graaf, Ruth O Payne, Iona Taylor, et al.
Human Vaccines & Immunotherapeutics|March 21, 2024
Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adultsPrasad S Kulkarni, Chandrasekaran Padmapriyadarsini, Johan Vekemans, et al.
Plos One|May 11, 2011
T cell responses to the RTS,S/AS01(E) and RTS,S/AS02(D) malaria candidate vaccines administered according to different schedules to Ghanaian childrenDaniel Ansong, Kwaku P Asante, Johan Vekemans, et al.
Plos One|July 7, 2015
Ad35.CS.01-RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve AdultsChristian F Ockenhouse, Jason Regules, Donna Tosh, et al.
Plos One|October 7, 2009
Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian childrenSeth Owusu-Agyei, Daniel Ansong, Kwaku Asante, et al.
The Lancet. Infectious Diseases|June 20, 2018
The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidatesNatalie I Mazur, Deborah Higgins, Marta C Nunes, et al.
The Journal of Infectious Diseases|June 17, 2016
Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAPTommy Rampling, Katie J Ewer, Georgina Bowyer, et al.
NPJ Vaccines|October 17, 2018
Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAPTommy Rampling, Katie J Ewer, Georgina Bowyer, et al.
The New England Journal of Medicine|November 5, 2025
Safety and Immunogenicity of an rVSV Lassa Fever Vaccine CandidateElissa Malkin, Marija Zaric, Mark Kieh, et al.
Pageof 12